USP22 promotes tumor progression and induces epithelial-mesenchymal transition in lung adenocarcinoma

Lung Cancer

Volumn 88, Issue 3, 2015, Pages 239-245

  Hu, Jing ^a   Yang, Dongdong ^a   Zhang, Huijuan ^a   Liu, Wei ^a   Zhao, Yanbin ^a   Lu, Hailing ^a   Meng, Qingwei ^a   Pang, Hui ^a   Chen, Xuesong ^a   Liu, Yanlong ^a   Cai, Li ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

EMT; Lung adenocarcinoma; Prognosis; TGF 1; USP22

Indexed keywords

ALPHA CATENIN; NERVE CELL ADHESION MOLECULE; ONCOPROTEIN; PROTEIN USP22; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; THIOL ESTER HYDROLASE; USP22 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMA CELL; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONCOGENE; ONCOGENE USP22; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION; ADENOCARCINOMA; AGED; CANCER STAGING; CELL MOTION; DISEASE COURSE; GENE SILENCING; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ADENOCARCINOMA; ADULT; AGED; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; THIOLESTER HYDROLASES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84929509387     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.02.019     Document Type: Article

References (46)

1. Jemal A., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Stewart D.J. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010, 75(3):173-234.
3. Chen C.H., et al. VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS ONE 2009, 4(4):e5052.
4. Ogawa E., et al. Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC). Ann Surg Oncol 2008, 15(2):547-554.
5. Rachet B., et al. Cancer survival in England and Wales at the end of the 20th century. Br J Cancer 2008, 99(Suppl. 1):S2-S10.
6. Reyes-Turcu F.E., Ventii K.H., Wilkinson K.D. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009, 78:363-397.
7. Love K.R., et al. Mechanisms: biology and inhibitors of deubiquitinating enzymes. Nat Chem Biol 2007, 3(11):697-705.
8. Daviet L., Colland F. Targeting ubiquitin specific proteases for drug discovery. Biochimie 2008, 90(2):270-283.
9. Nicholson B., et al. Deubiquitinating enzymes as novel anticancer targets. Future Oncol 2007, 3(2):191-199.
10. Glinsky G.V., Berezovska O., Glinskii A.B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Investig 2005, 115(6):1503-1521.
11. Glinsky G.V. Stemness genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol 2008, 26(17):2846-2853.
12. Glinsky G.V. Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle 2006, 5(11):1208-1216.
13. Zhang Y., et al. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol 2011, 137(8):1245-1253.
14. Liu Y.L., et al. Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer. J Surg Oncol 2011, 103(3):283-289.
15. Wang H., et al. Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma. Tumour Biol 2013, 34(3):1635-1639.
16. Hu J., et al. Expression patterns of USP22 and potential targets BMI-1: PTEN, p-AKT in non-small-cell lung cancer. Lung Cancer 2012, 77(3):593-599.
17. Piao S., et al. USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma. PLoS ONE 2012, 7(8):e42540.
18. Li J., Wang Z., Li Y. USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2012, 138(8):1291-1297.
19. Yang M., et al. Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics. Tumour Biol 2014, 35(2):929-934.
20. Yang D.D., et al. The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma. Cell Biochem Biophys 2011, 61(3):703-710.
21. Lv L., et al. Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells. Mol Cell Biochem 2011, 346(1-2):11-21.
22. Zhang X.Y., et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 2008, 29(1):102-111.
23. Lee K.K., et al. The deubiquitylation activity of Ubp8 is dependent upon Sgf11 and its association with the SAGA complex. Mol Cell Biol 2005, 25(3):1173-1182.
24. Berezovska O.P., et al. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006, 5(16):1886-1901.
25. Zhang X.Y., et al. USP22: an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle 2008, 7(11):1522-1524.
26. Liu Y.L., et al. USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys 2012, 62(1):229-235.
27. Atanassov B.S., et al. Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. Mol Cell 2009, 35(3):352-364.
28. Lin Z., et al. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell 2012, 46(4):484-494.
29. Larue L., Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005, 24(50):7443-7454.
30. Christofori G. New signals from the invasive front. Nature 2006, 441(7092):444-450.
31. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2(6):442-454.
32. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003, 15(6):740-746.
33. Imamura T., Oshima Y., Hikita A. Regulation of TGF-beta family signalling by ubiquitination and deubiquitination. J Biochem 2013, 154(6):481-489.
34. Cao Q., et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27(58):7274-7284.
35. Zhao Y., et al. A TFTC/STAGA module mediates histone H2A and H2B deubiquitination: coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell 2008, 29(1):92-101.
36. Ning Z., et al. USP22 promotes epithelial-mesenchymal transition via the FAK pathway in pancreatic cancer cells. Oncol Rep 2014, 32(4):1451-1458.
37. Inui M., et al. USP15 is a deubiquitylating enzyme for receptor-activated SMADs. Nat Cell Biol 2011, 13(11):1368-1375.
38. Dupont S., et al. FAM/USP9x: a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 2009, 136(1):123-135.
39. Meng J., et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS ONE 2010, 5(11):e14124.
40. Gao Y., et al. Expression of TGFbeta-1 and EHD1 correlated with survival of non-small cell lung cancer. Tumour Biol 2014, 35(9):9371-9380.
41. Bakin A.V., et al. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000, 275(47):36803-36810.
42. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J Clin Investig 2009, 119(6):1429-1437.
43. Zavadil J., Bottinger E.P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24(37):5764-5774.
44. Song L.B., et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Investig 2009, 119(12):3626-3636.
45. Ji M., et al. Ubiquitin specific protease 22 promotes cell proliferation and tumor growth of epithelial ovarian cancer through synergy with transforming growth factor β1. Oncol Rep 2015, 33(January (1)):133-140.
46. Zhao Y., et al. Ang II-AT1R increases cell migration through PI3K/AKT and NF-κB pathways in breast cancer. J Cell Physiol 2014, 229(November (11)):1855-1862.